10 results about "Pazopanib" patented technology

A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

This invention provides a combination for use in treating cancers that express prostate-specific membrane antigen (PSMA). [Solution] A combination comprising a PD-1 inhibitor, a CTLA-4 inhibitor, and a radiolabeled compound of formula Ia for use in treating PSMA-expressing cancer in the subject. JPEG2026049728000042.jpg45132 The aforementioned combination comprises one or more further anticancer agents, wherein the further anticancer agents are selected from octreotide, lanreotide, vapreotide, pasireotide, satreotide, everolimus, temozolomide, telotristat, sunitinib, sulfatinib, ribociclib, entinostat, and pazopanib.

The invention relates to a preparation method of pazopanib and an intermediate thereof, in particular to a preparation method of a structure as shown in a formula IV and a method for further preparing the pazopanib. 4-chloro-2-nitropyrimidine is used as an initial raw material and is sequentially subjected to substitution, reduction and alkylation reaction to obtain the pazopanib. The preparation method provided by the invention is a brand new technical route and is not reported in any literature and patent. According to the method, the yield of the product can be greatly improved, and the method is suitable for industrial production.

Provided are pharmaceutical compositions which include an amorphous solid dispersion comprising i) a lipophilic active pharmaceutical ingredient such as abiraterone, alectinib, pazopanib, cabozantinib, venetoclax, lurasidone, or vilazodone or a salt thereof, ii) a hydrophilic polymer, iii) optionally a surfactant, iv) optionally an adsorbent, and v) optionally an acid. Also described are methods for preparing such pharmaceutical compositions and treating a subject in need thereof. In one aspect, disclosed herein is an amorphous solid dispersion comprising an active pharmaceutical ingredient.

The invention provides a renal clear cell carcinoma pazopanib drug-resistant cell strain as well as a construction method and application thereof, the preservation number of the renal clear cell carcinoma drug-resistant cell strain is GDMCC NO: 65811, and the renal clear cell carcinoma drug-resistant cell strain is a pazopanib drug-resistant cell strain of 786-O. The Pazopanib is constructed in a manner of inducing the proliferation of kidney cancer cells 786-O in the Pazopanib by adopting a method of gradually increasing the concentration, and the drug resistance molecular mechanism of the Pazopanib is analyzed and read comprehensively through transcriptome, so that a new treatment idea is provided for clinically coping with the drug resistance of the Pazopanib.

Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.

The present invention provides a pazopanib-resistant renal clear cell carcinoma cell line, a construction method, and an application thereof. The deposit number of the renal clear cell carcinoma cell line is GDMCC NO: 65811. The renal clear cell carcinoma cell line is a 786-O pazopanib-resistant cell line. The cell line is constructed by inducing the proliferation of renal cancer cells 786-O in the presence of pazopanib by gradually increasing the concentration of pazopanib. Through comprehensive transcriptome analysis, the molecular mechanism of drug resistance is interpreted, providing a new treatment strategy for clinical treatment of drug resistance.

This application relates, in certain embodiments, to a method and composition for treating soft tissue sarcomas (STS, e.g., spindle cell sarcoma, solitary fibrous tumor, or leiomyosarcoma) using a composition comprising nanoparticles containing an mTOR inhibitor (e.g., limus drugs, e.g., sirolimus or its derivatives) and albumin in combination with a multityrosine kinase inhibitor (e.g., pazopanib).

A method for treating adenoid cystic carcinoma (ACC) is provided, comprising co-administering at least inhibitor of cyclin-dependent kinase 4 / 6 (CDK 4 / 6) and at least one multi-targeted receptor tyrosine kinase inhibitor (mtRTKI). The CDK 4 / 6 inhibitor may be at least one of palbociclib, abemaciclib and ribociclib and the mtRTKI may be at least one of sunitinib, sorafenib and pazopanib. A combination therapy with palbociclib and sunitinib provides a synergic effect in treatment of ACC.

Disclosed herein are nanoparticles comprising Pazopanib or a derivative thereof encapsulated by the copolymer poly (lactic-co-glycolic acid) (PLGA). Also disclosed herein are methods for treating osteoarthritis, inhibiting or preventing cartilage degeneration, and reducing or inhibiting pain-associated depression in subjects with joint pain with nanoparticles comprising Pazopanib or a derivative thereof.